Market movers: Eli Lilly, Echostar, BMO, Scotiabank, Trump Media, and Crypto.com announce strategic partnership

Eli Lilly's experimental oral obesity and diabetes drug, orforglipron, showed positive results in a Phase 3 trial. Trump Media & Technology Group Corp partnered with Crypto.com to integrate Cronos cryptocurrency into its platforms. EchoStar agreed to sell 50 MHz of nationwide wireless spectrum licenses to AT&T for $23 billion. Bank of Nova Scotia and Bank of Montreal reported better-than-expected Q3 results, driven by growth in their wealth management and US banking units.

Eli Lilly and Company (NYSE: LLY) reported positive topline results from the Phase 3 ATTAIN-2 trial, evaluating orforglipron, an investigational oral GLP-1 receptor agonist, in adults with obesity or overweight and type 2 diabetes. The trial demonstrated significant weight loss and A1C reductions, with a safety profile consistent with injectable GLP-1 medicines.

Orforglipron met the primary and all key secondary endpoints, delivering an average weight loss of 22.9 lbs (10.5%) on the highest dose at 72 weeks. Additionally, orforglipron lowered A1C by an average of 1.8% from a baseline of 8.1%. The drug also showed improvements in cardiometabolic risk factors, including non-HDL cholesterol, systolic blood pressure, and triglycerides. The highest dose of orforglipron reduced high-sensitivity C-reactive protein (hsCRP) levels by 50.6%.

The overall safety profile of orforglipron was consistent with the established GLP-1 receptor agonist class, with gastrointestinal-related adverse events being the most common. The most frequently reported adverse events included nausea, vomiting, diarrhea, constipation, and dyspepsia, all of which were generally mild-to-moderate in severity. Treatment discontinuation rates due to adverse events were balanced across the treatment groups.

Louis J. Aronne, MD, FACP, DABOM, a world-renowned obesity specialist, commented on the results, stating, "These data show the potential for orforglipron to offer an efficacy, safety, and tolerability profile consistent with the injectable GLP-1 class. Orforglipron could help healthcare providers expand treatment options for patients who prefer oral therapies without compromising clinical results."

Kenneth Custer, Ph.D., Lilly executive vice president and president of Lilly Cardiometabolic Health, noted, "The ATTAIN-2 results reinforce the potential for orforglipron, as a once-daily oral, to deliver meaningful weight loss and A1C reduction, consistent with similar landmark trials for injectable GLP-1s. With these positive data in hand, we are moving with urgency toward global regulatory submissions to potentially meet the needs of patients who are waiting."

Eli Lilly is now ready to submit the full clinical data package for orforglipron to regulatory authorities worldwide. If approved, the drug could offer a convenient, once-daily oral option for patients with obesity and type 2 diabetes.

References:
[1] https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-successful-third-phase-3-trial